Minimal Clinically Important Difference (MCID) of clinical endpoints in AIT

Minimal Clinically Important Difference (MCID) of clinical endpoints in AIT

This Task-Force initiative evaluates an important methodological question on trial-design methodology in AIT, the;”minimally clinical important difference (MCID)” of endpoints for assessing the clinical efficacy of AIT in trials.

IG: Allergen Immunotherapy

Chair: Oliver Pfaar

Secretary: Durham